✨ Free AI Report
4D Path Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research 4D Path Inc.
Company Research

4D Path Inc.: Business Overview, Financials & Competitive Analysis

4D Path's patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&E whole slide biopsy/resection images only. 4D Pa...

Analyst-debate audio for 4D Path Inc.

AskCyborg analysts argue the bull and bear cases for 4D Path Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

4D Path's physics-informed platform to democratize precision oncology through routine pathology images positions it at the...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest 4D Path Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

4D Path Inc. Overview

Pro stress-test →

4D Path's patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&E whole slide biopsy/resection images only. 4D Path's cloud-based, quantitative approach is intended to eliminate the need for additional molecular tests (e.g., immunohistochemistry, FISH, RNA-Seq, NGS), accelerating complete, actionable and objective insight leading to expedited and democratized precision medicine.

Strategic Profile

Pro stress-test →

Led by CEO Jacopo Leonardi, 4D Path has created a platform, the patented Q-Plasia OncoReader (QPOR), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient's response to therapy. In April 2026, Versiti Clinical Trials Services (VCTS) launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments.

Competitive Landscape

Pro stress-test →

4D Path specializes in cancer diagnostics using a patented platform that leverages statistical physics and tumor biology and offers an end-to-end automated platform for biomarker typing and prognostication from H&E images, serving pathologists, oncologists, and patients. Primary competitors include digital pathology and AI-powered diagnostic platforms (Proscia, TRIBVN Healthcare, Qritive) that use image-based analysis for cancer diagnosis and workflow automation. 4D Path's differentiation centers on its physics-informed quantification of cell cycle and immune dynamics to predict treatment response, versus general-purpose digital pathology or image analysis solutions.

Industry Context

4D Path Inc. operates in Oncology Drugs.

Key facts

Founded: 2016 · Headquarters: Newton, Massachusetts, US · Employees: 17 · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on 4D Path Inc..

  • Proprietary Q-Plasia OncoReader platform quantifies cell cycle dysfunction and immune microenvironment directly from standard H&E staining, potentially displacing costly molecular testing workflows
  • (May 2026) Recent strategic funding round coupled with board appointments (Katherine Vega Stultz, Robert J. Hombach) signals investor confidence and institutional credibility in precision oncology space
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Closed strategic financing round with appointment of Katherine Vega Stultz and Robert J. Hombach to Board of Directors
  • April 2026Partnership launched with Versiti Clinical Trials Services to integrate 4D Path's treatment predictive biomarker technology into clinical research workflows
  • +1 moreTrack every material event for 4D Path Inc. as it happens. Explore monitoring →
Get alerted when 4D Path Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare 4D Path Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

4D Path Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about 4D Path Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 4D Path Inc. and its top competitor on Cyborg Score”
“What did 4D Path Inc. do this quarter?”
“Is 4D Path Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does 4D Path Inc. do?+
4D Path's patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&E whole slide biopsy/resection images only. 4D Pa...
What is 4D Path Inc.'s Cyborg Score?+
4D Path Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 4D Path Inc.'s main competitors?+
Named competitors include Proscia, TRIBVN Healthcare, Qritive. The full competitive landscape is in the AskCyborg report.
How can I get the full 4D Path Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 4D Path Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 4D Path Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual